Novo and Takeda are set to exit antibody therapy developer Symphogen in an acquisition by one of its strategic partners, Servier.
Pharmaceutical company Servier has agreed to purchase Symphogen, a Denmark-based cancer therapy developer backed by pharmaceutical firms Novo and Takeda, for an undisclosed sum.
Founded in 2000, Symphogen is developing oncology and immuno-oncology drugs using its proprietary antibody discovery technology. Its two lead assets focus on metastatic colorectal cancer and lung cancer respectively.
In addition to its proprietary pipeline, the company has strategic partnerships in place with Servier for indications such as metastatic solid tumours and lymphomas, and with biotechnology…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
